SAN FRANCISCO, May 4, 2016 /PRNewswire/ -- Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced that Jocelyn Jackson, Chief Financial Officer, will present at the following upcoming events:
BioEquity Europe 2016
Date: Wednesday, May 11, 2016
Time: 2:00 p.m. CEST
Location: Scandic Hotel Copenhagen, Denmark
Bay Area Biotech Forum
Date: Wednesday, May 18, 2016
Time: 7:30 - 10:00 a.m. PDT
Location: San Francisco Marriott Marquis, Golden Gate Ballroom A
About Symic
Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic's proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.
For additional information please visit the company's website at http://www.symic.bio, LinkedIn page www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.
Media Contacts
David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
SOURCE Symic